JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Y-27632 is a specific inhibitor of Rho-associated kinases (ROCK) family with Ki values of 0.22 μM and 0.30 μM for ROCK1 and ROCK2, respectively.
Y-27632 has shown selectivity of inhibition by comparing their Ki values for other Rho effector kinases, citron kinase and PKN, as well as PKCα. The Ki values of Y-27632 for citron kinase and PKN are least 20-fold higher, and Ki values for PKCα are about 200-fold higher than those for ROCK kinases. In addition, Y-27632 has been reported to inhibit ROCK1 and ROCK2 by competing with ATP for binding to the kinase in HeLa cells. Besides, Y-27632 has also shown the inhibition of stress fibers in Swiss 3T3 cells when the concentration of Y-27632 is 10 μM [1].
References:[1] Ishizaki T1, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
Binding assays
Recombinant ROCK-I, ROCK-II, PKN, or citron kinase was expressed in HeLa cells as Myc-tagged proteins by transfection using Lipofectamine, and was precipitated from the cell lysates by the use of 9E10 monoclonal anti-Myc antibody coupled to G protein-Sepharose. Recovered immunocomplexes were incubated with various concentrations of [32P] ATP and 10 mg of histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632 at 30°C for 30 min in a total volume of 30 mL of the kinase buffer (50 mM HEPES-NaOH, pH 7.4, 10 mM MgCl2, 5 mM MnCl2, 0.02% Briji 35, and 2 mM dithiothreitol). PKCa was incubated with 5 mM [32P] ATP and 200 mg/mL histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632at 30°C for 10 min in a kinase buffer (50 mM Tris-HCl, pH 7.5, 0.5 mM CaCl2, 5 mM magnesium acetate, 25 mg/mL phosphatidyl serine, 50 ng/mL 12-O-tetradecanoylphorbol-13-acetate and 0.001% leupeptin) in a total volume of 30 mL. Incubation was terminated by 43 Laemmli sample buffer (10 mL).
Cell lines
HeLa cells, Swiss 3T3 cells
Preparation method
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting condition
0.3 and 1 μM, 30 min or 24 h
Applications
Y-27632 inhibited the kinase activity of both ROCK-I and ROCK-II in vitro, and this inhibition was reversed by ATP in a competitive manner. Y-27632 abolished stress fibers in Swiss 3T3 cells at 10 μM, but the G1-S phase transition of the cell cycle and cytokinesis were little affected at this concentration. In Swiss 3T3 cells, prior treatment of cells with Y-27632 for 30 min prevented cell shape and actin-stress fibers changes in a concentration-dependent manner; almost complete inhibition was observed at 10 μM. 10 and 100 μM Y-27632 prolonged the lag time and delayed the appearance of BrdU-labeled cells in a concentration-dependent manner, delays of about 1 and 4 h. In HeLa cells, 30 μM Y-27632 inhibited cytokinesis.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases[J]. Molecular pharmacology, 2000, 57(5): 976-983.